{"name":"Tango Therapeutics","slug":"tango","ticker":"TNGX","exchange":"NASDAQ","domain":"tangotx.com","description":"Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase (STK) 11 loss-of-function mutations to treat lung cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.","hq":"Cambridge, MA","founded":0,"employees":"137","ceo":"Barbara Weber","sector":"Oncology / Precision Medicine","stockPrice":20.11,"stockChange":0.31,"stockChangePercent":1.57,"marketCap":"$2.9B","metrics":{"revenue":62384000,"revenueGrowth":-100,"grossMargin":-111.9,"rdSpend":132165000,"netIncome":-101594000,"cash":343137984,"dividendYield":0,"peRatio":-12.6,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"TTX-080 patent cliff ($0.0B at risk)","drug":"TTX-080","type":"patent_expiry","sentiment":"negative"},{"date":"2032-06-01","label":"TTX-060 patent cliff ($0.0B at risk)","drug":"TTX-060","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-22","type":"earnings","headline":"Tango Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Tango Therapeutics reported its fourth quarter and full year 2023 financial results, highlighting progress in its pipeline and strong cash position.","drugName":"","sentiment":"neutral"},{"date":"2023-11-14","type":"deal","headline":"Tango Therapeutics Announces Collaboration with Merck KGaA to Develop Cancer Therapies","summary":"Tango Therapeutics announced a collaboration with Merck KGaA to develop cancer therapies targeting genetically defined cancer subtypes.","drugName":"","sentiment":"positive"},{"date":"2023-08-01","type":"trial","headline":"Tango Therapeutics Announces Initiation of Phase 2 Clinical Trial for TTX-080 in Solid Tumors","summary":"Tango Therapeutics announced the initiation of a Phase 2 clinical trial for TTX-080 in solid tumors.","drugName":"","sentiment":"neutral"}],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-03-16","type":"trial","source":"simplywall.st","summary":"Does Tango Therapeutics (TNGX) Trial Pact and ESOP Shelf Hint at a Pivotal Strategic Turn? - simplywall.st","headline":"Does Tango Therapeutics (TNGX) Trial Pact and ESOP Shelf Hint at a Pivotal Strategic Turn?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxPWjRQMDJVanZ2bkNCZmlkMjlGOWIyeHlSdEdUSF9hWGl0WUZfQmpRX2RGaU5oM0NMZlhVTVJQRnlWYm9tby1XOUJ1UUNISVNJdmtTVHZCQ2p1dE80b2Vsa3RqYWdzT2lfX2p6b010aEt2U2NOb05oNGJudGptUERUUkJoaXhlY3JySVpTaGV5S3o2OTR2Yi1sY0tTTQ?oc=5","date":"2026-03-09","type":"pipeline","source":"Yahoo Finance","summary":"X4 Pharmaceuticals, Immuneering and Tango Therapeutics Are Getting New Analyst Attention - Yahoo Finance","headline":"X4 Pharmaceuticals, Immuneering and Tango Therapeutics Are Getting New Analyst Attention","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxOUWp3TDRzY1g4NUxBRHhUYm5mTFpsbXlQdEFZeVZGU0toMUpveXFKdW1SdWIxTEMwc2pyRjA2eEY3MUZDQ194cDItck4zX2lvLTBGZDI5OFNkdVNBYTVMd2NaTmhCa2RDX3dBdlV4bDI2QlBIWE50eU9xSU1XeHpkUg?oc=5","date":"2026-03-07","type":"deal","source":"Finviz","summary":"Tango Therapeutics (TNGX) Soars 52% on Buy Reco - Finviz","headline":"Tango Therapeutics (TNGX) Soars 52% on Buy Reco","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxOOE14NWJGcm1NQTJacTd0VHpGek1RVkVOMHBzVE45dE80U1BySVFpWlJQb1hQX1J2dDVPMkpnNkpyZlRUQ3N3MXRDTEpVOThPUGhWMGRlckI2WWNjOXZGYk50MWlXcU1INDkzNndNNXd3ZUZ1T2Vpb2E0UnNhR3lUVjdQT0FSOWFFSlFBdmFsSDR6TXdhS3BrZkZmVzdtS3pTQkZvQ0pheHRocXE1V2pHMWRlWQ?oc=5","date":"2026-03-06","type":"deal","source":"Seeking Alpha","summary":"Tango Therapeutics: I'm Not Buying Into Latest Rally, Despite PRMT5 Promise (NASDAQ:TNGX) - Seeking Alpha","headline":"Tango Therapeutics: I'm Not Buying Into Latest Rally, Despite PRMT5 Promise (NASDAQ:TNGX)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxOVWhzQ2lGLUV4WVVkWlRBUUwyUlpoTmh3WHpkeXVscEVLdzNmY1BMSmtETFBGSFpQM0FEYjM3anBfcl9Eb2NLb1lralBZb3Z2R1lwLWJjOFBLdVFBUmhCZjR2cjhpYmhuU0xFUnlhMDlCMkZQNS0zc0NqemNtdzhPWE8zdmZiSUduQkZXWGt5ZEVtV0NHNTZqOFVaWDJNYzdvMkF0Q3czUmFrelNRcktJc2tlMm5EbGNDNVptMFlQbw?oc=5","date":"2026-03-06","type":"deal","source":"TradingView","summary":"TNGX Stock Hits Record High on Inking Collaboration Deal With ERAS - TradingView","headline":"TNGX Stock Hits Record High on Inking Collaboration Deal With ERAS","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxObkdHbU53NnBqWEZmY0Z1dFRnMzdnb2tDRV9BdDBwUGJXcG1xMmNnNm5OX1J5alloVVRDTkdFSng3RnpLSzdPTElRRnlUbS04LWNPM2tUTHkxRm5XRDdjVkxQd0F1VXJZWjVuOG9iV1RyTnA1dFY1bUpxZ1R4eDRlNHNWcGM5UndZckJkUVA2REZDVGk5TmQ4TzdTdl85SjA?oc=5","date":"2026-03-05","type":"pipeline","source":"Finviz","summary":"Tango Therapeutics (TNGX) Hits All-Time High as Analyst Turns Bullish - Finviz","headline":"Tango Therapeutics (TNGX) Hits All-Time High as Analyst Turns Bullish","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxNTWtaWnE4VWhMQ2RtYkVBRW10QkRmb2xWaE5NOGZKMC1pcXlFRDJIR251Ymd2Q2FaOHpha1E0Wm4zd09MZ1h5VGhvWUdsS0I5ZWZPcC1oOXBlaHZEd2pjLVZCMkp4N2x0X2VPdGtDQzQ1YnhWTllIMFRWLVYxZ2VBaTFsWFBoaFRLTlBPcFYyYkNVVXZqMTRwaXMwd28?oc=5","date":"2026-03-05","type":"deal","source":"Mugglehead Magazine","summary":"Tango Therapeutics rallies after oncology drug collaboration with Erasca - Mugglehead Magazine","headline":"Tango Therapeutics rallies after oncology drug collaboration with Erasca","sentiment":"neutral"},{"date":"2026-03-05","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-05","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4gFBVV95cUxNWUd3OHplcGFUZUp3cGFCQU93dFV0a3lHVkxYVlhSSEkzdTR3YTJlSjdLaWg5MmE2U2x4ZzhSbGdiamx2MUd4cExmcm1yYmxrT0pMV1VoeTAySDY4UXVmRy1ZekNwOWUzbDUxMEhBOXAwSnRRWDdLYkdhb3VYQ1NtV0s4OGZmMjY4dXg1YWphdGJxOW5wZDRmVGJUVGp5bFNsMHhWdDd6dXM0Q1I1emRoTHp0NEwzRDZkME9aMXkzbVJVN0h5YTQ1Z3dYcE9CNzVveGdSLVBSek5LQWZndGRGSDR3?oc=5","date":"2026-03-04","type":"pipeline","source":"The Motley Fool","summary":"Investment Firm Bets Big on TNGX Stock With $9.5 Million Purchase, According to Recent SEC Filing - The Motley Fool","headline":"Investment Firm Bets Big on TNGX Stock With $9.5 Million Purchase, According to Recent SEC Filing","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTE1hbnZVaWNvbXVJeExkMjF2U016WEFWdFV1eU5XZFRFakFaMEFUbng2Rml1Y0twdWlYeGdzYUQ4UkVrQjk4c05EMElMM2pXejBiclJvWFFHeGdSNzdLVlJHWUV6ZDVlQ0s1bHZVT19iT1NUVWZGOVVNVnR6SG1IVjg?oc=5","date":"2025-12-22","type":"pipeline","source":"Yahoo Finance","summary":"3 Biotech Stocks Wall Street Analysts Are Bullish on for 2026 - Yahoo Finance","headline":"3 Biotech Stocks Wall Street Analysts Are Bullish on for 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxOeDdpUkJFWDBDbTZlTkZOZDV5T1JXbnVTR1AwZ19fdksyak9tdHZvTi1qbTlTNUU2bTdHV3kwYlRFVTZDNGpiQU1nTnNUYVB5ZFhFNUhCWlljUGRmYVRnOVJnNTNFeFhVUDBTd1VQNDlOR2V3ZjJPZUN3NlBlZHV3RlJMZkJMRmZOZHZTS19LVkJTM0pjNmtWRnZxOA?oc=5","date":"2025-10-24","type":"pipeline","source":"The Pharma Letter","summary":"Tango Therapeutics announces $225 million financing - The Pharma Letter","headline":"Tango Therapeutics announces $225 million financing","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-05-15","type":"pipeline","source":"simplywall.st","summary":"US$10.43: That's What Analysts Think Tango Therapeutics, Inc. (NASDAQ:TNGX) Is Worth After Its Latest Results - simplywall.st","headline":"US$10.43: That's What Analysts Think Tango Therapeutics, Inc. (NASDAQ:TNGX) Is Worth After Its Latest Results","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUEFVX3lxTE9sODJLLVp0WFVrZmRTS3loemJ2dFBXSlR3WEJWV0h1NGxTLUFseWhmV2JITjFtZXdjcjZmT2wwUUozZElOOGZ1WThwLUZaWWhh?oc=5","date":"2024-05-16","type":"pipeline","source":"CNN","summary":"symbol__ Stock Quote Price and Forecast - CNN","headline":"symbol__ Stock Quote Price and Forecast","sentiment":"neutral"}],"patents":[{"drugName":"TTX-080","drugSlug":"ttx-080","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":0},{"drugName":"TTX-060","drugSlug":"ttx-060","patentNumber":"","type":"Patent Cliff","expiryDate":"2032-06-01","territory":"US","annualRevenue":0}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":["Bristol Myers Squibb","Merck & Co.","Roche Holding"],"therapeuticFocus":["Oncology","Precision Medicine"],"financials":{"source":"sec_edgar","revenue":62384000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":62384000,"period":"2025-12-31"},{"value":42069000,"period":"2024-12-31"},{"value":42069000,"period":"2024-12-31"},{"value":36527000,"period":"2023-12-31"},{"value":36527000,"period":"2023-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":132165000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-101594000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":398690000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":20.11,"previousClose":19.8,"fiftyTwoWeekHigh":22.2,"fiftyTwoWeekLow":1.03,"fiftyTwoWeekRange":"1.03 - 22.2","fiftyDayAverage":15.09,"twoHundredDayAverage":9.69,"beta":1.31,"enterpriseValue":2515671296,"forwardPE":-12.6,"priceToBook":7.9,"priceToSales":46,"enterpriseToRevenue":40.33,"enterpriseToEbitda":-23.08,"pegRatio":0,"ebitda":-109008000,"ebitdaMargin":-174.7,"freeCashflow":-60859624,"operatingCashflow":-138886000,"totalDebt":33570000,"debtToEquity":9.7,"currentRatio":16.32,"returnOnAssets":-19.5,"returnOnEquity":-37.2,"analystRating":"1.3 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":10,"targetMeanPrice":21.4,"targetHighPrice":30,"targetLowPrice":16,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":1.3,"institutionHeldPercent":121.1,"sharesOutstanding":142688851,"floatShares":67744386,"sharesShort":47246429,"shortRatio":12.21,"shortPercentOfFloat":33.1,"epsTrailing":-0.87,"epsForward":-1.59,"revenuePerShare":0.54,"bookValue":2.55,"officers":[{"age":67,"name":"Dr. Barbara L. Weber M.D.","title":"Founder & Executive Chair"},{"age":63,"name":"Dr. Malte  Peters M.D.","title":"President, CEO & Director"},{"age":46,"name":"Ms. Daniella  Beckman CPA","title":"Chief Financial Officer"},{"age":47,"name":"Dr. Adam S. Crystal M.D., Ph.D.","title":"President of Research & Development"},{"age":63,"name":"Prof. Alan  Ashworth FRS, Ph.D.","title":"Founder & Member of Scientific Advisory Board"},{"age":67,"name":"Dr. William G. Kaelin Jr., M.D.","title":"Founder & Member of Scientific Advisory Board"},{"age":58,"name":"Dr. Antoni  Ribas M.D., Ph.D.","title":"Founder & Member of Scientific Advisory Board"},{"age":null,"name":"Dr. Michael  Palmieri Ph.D.","title":"Chief Technical Operations Officer"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.tangotx.com","phone":"857 320 4900"}}